scholarly journals Case: Bacillus Calmette-Guerin (BCG)-induced Reiter syndrome with an attempt at repeat BCG induction

2017 ◽  
Vol 12 (1) ◽  
pp. E37-9 ◽  
Author(s):  
Douglas C. Cheung ◽  
Alexandra L. Millman ◽  
Robert J. Hamilton
Keyword(s):  
Disease Control ◽  
Initial Treatment ◽  
Bacillus Calmette Guerin ◽  
Duration Of Disease ◽  
Reiter Syndrome

We present a case of BCG-induced Reiter syndrome with 19-year followup, and the first instance of BCG re-induction in this cohort of patients. This was attempted given the substantial duration of disease control following the initial treatment.

scholarly journals Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

2010 ◽  
Vol 28 (5) ◽  
pp. 767-772 ◽  
Author(s):  
Samuel A. Wells ◽  
Jessica E. Gosnell ◽  
Robert F. Gagel ◽  
Jeffrey Moley ◽  
David Pfister ◽  
...  
Keyword(s):  
Growth Factor ◽  
Disease Control ◽  
Initial Treatment ◽  
Therapeutic Option ◽  
Locally Advanced ◽  
Growth Factor Receptor ◽  
Effective Therapy ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Serum Carcinoembryonic Antigen

Purpose There is no effective therapy for patients with distant metastasis of medullary thyroid carcinoma (MTC). Activating mutations in the RET proto-oncogene cause hereditary MTC, which provides a strong therapeutic rationale for targeting RET kinase activity. This open-label, phase II study assessed the efficacy of vandetanib, a selective oral inhibitor of RET, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, in patients with advanced hereditary MTC. Methods Patients with unresectable locally advanced or metastatic hereditary MTC received initial treatment with once-daily oral vandetanib 300 mg. The dose was adjusted additionally in some patients on the basis of observed toxicity until disease progression or any other withdrawal criterion was met. The primary assessment was objective tumor response (by RECIST [Response Evaluation Criteria in Solid Tumors]). Results Thirty patients received initial treatment with vandetanib 300 mg/d. On the basis of investigator assessments, 20% of patients (ie, six of 30 patients) experienced a confirmed partial response (median duration of response at data cutoff, 10.2 months). An additional 53% of patients (ie, 16 of 30 patients) experienced stable disease at ≥ 24 weeks, which yielded a disease control rate of 73% (ie, 22 of 30 patients). In 24 patients, serum calcitonin levels showed a 50% or greater decrease from baseline that was maintained for at least 4 weeks; 16 patients showed a similar reduction in serum carcinoembryonic antigen levels. The most common adverse events were diarrhea (70%), rash (67%), fatigue (63%), and nausea (63%). Conclusion In this study, vandetanib demonstrated durable objective partial responses and disease control with a manageable adverse event profile. These results demonstrate that vandetanib may provide an effective therapeutic option in patients with advanced hereditary MTC, a rare disease for which there has been no effective therapy.

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement

2011 ◽  
Vol 29 (3) ◽  
pp. 1896-1907 ◽  
Author(s):  
C. Porta ◽  
G. Tortora ◽  
C. Linassier ◽  
K. Papazisis ◽  
A. Awada ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Disease Control ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Targeted Agents ◽  
Duration Of Disease

scholarly journals Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan

Blood ◽  
1975 ◽  
Vol 45 (2) ◽  
pp. 197-203
Author(s):  
GP Canellos ◽  
RC Young ◽  
PE Neiman ◽  
VT Jr DeVita
Keyword(s):  
Disease Control ◽  
Leukocyte Count ◽  
Skin Pigmentation ◽  
Philadelphia Chromosome ◽  
Chronic Phase ◽  
Remission Induction ◽  
Chronic Granulocytic Leukemia ◽  
Duration Of Disease ◽  
Granulocytic Leukemia ◽  
Primary Agent

Dibromomannitol (DBM) is a new agent for the treatment of chronic granulocytic leukemia. A propsective evaluation of the drug was undertaken in a randomized comparison with busulfan. Forty previously untreated, Philadelphia chromosome-positive cases were treated, with 20 patients in each treatment group. The protocol provided for continuous maintenance therapy after remission induction, with a crossover to the opposite drug in patients who became refractory to the primary agent but are without evidence of blastic tranformation. There were 14 remissions in the DBM group and 15 in those treated with busulfan. The rate of decrease of the elevated leukocyte count was more rapid with DBM, but prolonged disease control off treatment occurred in only three of 14 cases as opposed to nine of fifteen busulfan-treated patients who required a median delay of 12 mo before maintenance could be initiated. Hypoplasia occurred in one DBM patient and two busulfan cases. Following recovery, crossover to the opposite drug in two cases again resulted in hypopllasia. Increased skin pigmentation, amenorrhea, pulmonary fibrosis, and cytologic dysplasia, commonly associated with busulfan adminstration, were also noted with DBM. The median duration of disease control with busulfan was 34 mo and 26 mo with DBM. There was no signigicant difference in the incidence of blastic transformation, and median survival for both groups was 44 mo. DBM appears to be as effective as busulfan in the treatment of the chronic phase of CGL but with a more predictable myelosuppressive action. The principal advantage of busulfan over DBM is the fact that more than half the busulfan-treated patients experienced prolonged disease control off treatment.

Did Patients With Interstitial Cystitis Who Failed to Respond to Initial Treatment With Bacillus Calmette-Guerin or Placebo in a Randomized Clinical Trial Benefit From a Second Course of Open Label Bacillus Calmette-Guerin?

2007 ◽  
Vol 178 (3) ◽  
pp. 886-890 ◽  
Author(s):  
Kathleen Joy Propert ◽  
Robert Mayer ◽  
J. Curtis Nickel ◽  
Christopher K. Payne ◽  
Kenneth M. Peters ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Interstitial Cystitis ◽  
Randomized Clinical Trial ◽  
Initial Treatment ◽  
Bacillus Calmette Guerin ◽  
Open Label

Use of Petroleum Derived Spray Oils in Washington Grapevine Powdery Mildew Management Programs

2005 ◽  
Vol 6 (1) ◽  
pp. 14
Author(s):  
G. G. Grove ◽  
J. Lunden ◽  
S. Spayd
Keyword(s):  
Powdery Mildew ◽  
Disease Control ◽  
Initial Treatment ◽  
Visual Detection ◽  
Titratable Acidity ◽  
Growing Season ◽  
Soluble Solids ◽  
Fungicide Treatment ◽  
Grapevine Powdery Mildew ◽  
Eastern Washington

The effects of petroleum-derived spray oils (PDSO) on powdery mildew control and selected berry characteristics were evaluated in vineyards in eastern Washington during 2001 and 2002. Up to seven PDSO applications were made during each growing season between the 15-to-30-cm shoot stage and veraison. The use of oil decreased total soluble solids (TSS) at harvest by 0.17% per application but had no significant effects on berry weight, pH, or titratable acidity. Because of their documented eradicant and antisporulant properties, PDSO were also utilized as the initial treatment in fungicide treatment sequences initiated upon the first visual detection of powdery mildew signs in the vineyard. When used in this fashion very early in powdery mildew epidemics, PDSO helped to reduce fungicide usage and input costs without compromising disease control. Accepted for publication 15 February 2005. Published 17 March 2005.

A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 3514-3514 ◽  
Author(s):  
Aparna Raj Parikh ◽  
Jeffrey William Clark ◽  
Jennifer Yon-Li Wo ◽  
Beow Y Yeap ◽  
Jill N. Allen ◽  
...  
Keyword(s):  
Disease Control ◽  
Median Duration ◽  
Checkpoint Blockade ◽  
Cellular Damage ◽  
Significant Activity ◽  
Open Label ◽  
Intention To Treat ◽  
Duration Of Disease ◽  
Dual Blockade ◽  
Tumor Biopsies

3514 Background: mCRC remains a lethal cancer and immunotherapy in MSS mCRC has yet to show significant activity. In preclinical models, radiation induced cellular damage may increase responsiveness to immunotherapy via the abscopal effect, with evidence for synergy between radiation therapy (RT) and dual checkpoint blockade. In this study, we assessed dual blockade of CTLA-4 and PD-1 combined with RT as a strategy to stimulate an immune response for patients with MSS mCRC. Methods: In this open-label, single arm phase-2 study, we enrolled 40 MSS mCRC patients (pts). Eligible pts had histologically-confirmed MSS mCRC, ECOG PS 0-1, and progression on at least two lines of therapy. Treatment (Tx) consisted of ipilimumab (1mg/kg q6 weeks), nivolumab (240 mg q2 weeks) and 3 fractions of 8 Gy of RT at cycle 2 every other day. Tx continued until progression, discontinuation or withdrawal. The primary endpoint was Disease Control Rate (DCR), with radiological evaluations every 3 months. Exploratory endpoints included ORR, PFS, OS and safety. Response was defined as disease control outside the radiation field. We obtained serial tumor biopsies pre-tx, during checkpoint blockade alone (cycle 1) and 2 weeks after initiation of radiation. Intention-to-treat analysis (ITT) includes all pts receiving at least one dose of study agent. Results: 40 pts (median age 59 years (26-83), 58% male) enrolled and started treatment from 7/2017 to 12/2018. DCR was 17.5% (7/40) with a 7.5% (3/40) ORR by ITT. Median duration of disease control was 77 days in the ITT; 252 days for those with disease control (n=7) based on the first re-staging scans at 3 months or censored (n=3) and 70.5 days for pts with PD (n=17) or who did not receive RT due to clinical progression (n=13). In the modified ITT (all pts receiving RT and restaged), N=24 pts, excluding 1 pt pending 1st scans post-RT, DCR was 29.2% (7/24) and ORR 12.5% (3/24). Median duration of disease control in mITT was 77.5 days: 252 days for those with disease control and 77 days for those with PD. TRAEs were reported in 22/40 (55%). 20/40 (50%) with grade ≥3 toxicities, with fatigue, nausea, vomiting, diarrhea, infusion-related reaction and dyspnea being the most common. 1(2%) pt died of respiratory failure possibly related to tx. Conclusions: Dual blockade of CTLA-4 and PD-1 with RT is feasible and demonstrates durable activity in pts with MSS mCRC. There are 3 pts who have not completed RT or had their post-RT re-staging. We will report updated efficacy data and outcomes from correlative serial tumor biopsies upon trial completion. Clinical trial information: NCT03104439.

Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study.

1988 ◽  
Vol 6 (2) ◽  
pp. 261-269 ◽  
Author(s):  
M Perloff ◽  
G J Lesnick ◽  
A Korzun ◽  
F Chu ◽  
J F Holland ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Disease Control ◽  
Combined Modality Therapy ◽  
Local Tumor Control ◽  
Stage Iii ◽  
Tumor Control ◽  
Duration Of Disease ◽  
Group B ◽  
To Receive

One hundred thirteen evaluable patients with previously untreated stage III breast carcinoma were treated with three monthly cycles of cyclophosphamide (CYC), doxorubicin (DOX), 5-fluorouracil (5-FU), vincristine (VCR), and prednisone (PRED) (CAFVP). Subsequently, 91 (81%) were deemed operable. Patients were then randomized to receive surgery or radiotherapy (RT) to determine which of these modalities afforded better local tumor control. All patients also received 2 additional years of CAFVP in a further attempt to eradicate local disease and systemic micrometastases. Forty-one of the randomized patients have relapsed. Approximately half of the initial relapses in each arm were local. The overall duration of disease control was similar following either modality, with a median of 29.2 months for surgery patients and 24.4 months for RT patients. Similarly, there was no major difference in survival related to randomized treatment with an overall median of 39 months (median follow-up 37 months). Pre- or perimenopausal status and inflammatory disease were associated with shorter disease control and survival. Treatment was generally well tolerated and toxicity was acceptable. This study demonstrates that prolonged control of stage III breast carcinoma can be achieved with combined modality therapy in which cytotoxic chemotherapy precedes and follows treatment directly primarily at the breast tumor, using either surgery or RT. Nevertheless, new regimens must be designed if significant advances that may lead to the cure of this disease are to be achieved.

scholarly journals Clinical Study on Part Factors Affecting the Effect of Platelet Transfusion during Hematopoietic Stem Cell Transplantation

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4987-4987
Author(s):  
Jie Yang ◽  
Xiuwen Li ◽  
Bao-An Chen
Keyword(s):  
Logistic Regression ◽  
Regression Analysis ◽  
Stem Cell ◽  
Initial Treatment ◽  
Platelet Transfusion ◽  
Conditional Logistic Regression ◽  
Hematopoietic Stem ◽  
Conditional Logistic Regression Analysis ◽  
Factors Affecting ◽  
Duration Of Disease

Objective :At present, patients with hematopoietic stem cell transplantation (HSCT) are gradually increasing due to hematological diseases. However, there are no further studies on the factors affecting the effect of platelet transfusion during HSCT. This study analyzed the possible factors that affect the platelet transfusion efficiency. Methods: The clinical data of patients with HSCT were collected from the Department of Hematology, Zhongda Hospital Affiliated to Southeast University from March 2015 to March 2018. According to the inclusion and exclusion criteria, a retrospective statistical analysis on the factors affecting the infusion effect was taken in all patients from +1 d to the day that the peripheral blood granulocyte count was more than 0.5×109/L after transplantation. The factors are including gender, age, types of disease, whether initial treatment, platelet inventory days in the effective period, types of transplantation, duration of disease and transfusion times. Furthermore, non-conditional logistic regression analysis was performed on the mentioned factors with statistical significance. Results: A total of 52 patients, 299 platelet transfusions were included in this study. The patients involve 28 men and 24 women, and there were 233 effective infusion and 66 invalid infusion. After chi-square test, the effects of gender, age, disease types, whether initial treatment, transplantation types, duration of disease and transfusion times on platelet transfusion were statistically significant(P<0.05), while platelet inventory days within the validity period had no statistically significant effect on platelet transfusion (P≥0.05). Furthermore, the results of non-conditional logistic regression analysis showed that gender, disease type and whether initial treatment had a statistically significant impact on the effect of platelet transfusion (P<0.05). Conclusion: There are many factors related to poor platelet transfusion during HSCT, in which the gender, disease types and whether initial treatment are the main influencing factors. Disclosures No relevant conflicts of interest to declare.

scholarly journals Fungicidal Suppression of Swiss Needle Cast and Pathogen Reinvasion in a 20-Year-Old Douglas-Fir Stand in Oregon

2007 ◽  
Vol 22 (4) ◽  
pp. 248-252 ◽  
Author(s):  
Jeffrey K. Stone ◽  
Paul W. Reeser ◽  
Alan Kanaskie
Keyword(s):  
Disease Control ◽  
Douglas Fir ◽  
Detectable Effect ◽  
Coast Range ◽  
Oregon Coast Range ◽  
Needle Cast ◽  
Final Treatment ◽  
Swiss Needle Cast ◽  
Duration Of Disease ◽  
Effect Of Treatment

Abstract Aerial applications of chorothalonil fungicide were carried out annually over 5 consecutive years, 1996–2000, on three sets of paired, 2-ha units in a Douglas-fir plantation affected by Swiss needle cast in the Oregon Coast Range. The effect of treatment on disease control was evaluated annually from 2001 to 2004. One- and 2-year-old foliage in the fungicide-treated units had fewer fruiting bodies of the pathogen Phaeocryptopus gaeumannii compared with the unsprayed units for foliage sampled in 2001. Total needle retention was also greater in the fungicide-treated units after five consecutive annual fungicide applications. Reduced P. gaeumannii infection in the fungicide-treated units persisted for foliage produced in 2001, which did not receive direct fungicide treatment. Reduced infection levels in the 2001 foliage cohort in the treated units was presumed to be due to the effect of disease control on inoculum production. At 4 years following the final treatment application, infection levels averaged over four foliage cohorts (2000–2003) remained significantly smaller for the fungicide-treated units. Trees in fungicide-treated units retained 10–50% of the 2000 needle cohort (4-year-old needles) and 25–60% of the 2001 cohort in May 2004. However, there was no detectable effect of treatment on infection for 2002 foliage sampled in 2003 or for 2003 foliage sampled in 2004 (1-year-old needles), suggesting that the duration of disease control was relatively brief.

scholarly journals Treatment of chronic granulocytic leukemia with melphalan

Blood ◽  
1978 ◽  
Vol 51 (4) ◽  
pp. 571-577
Author(s):  
T Hauch ◽  
G Logue ◽  
J Laszlo ◽  
E Cox ◽  
W Rundles
Keyword(s):  
Side Effects ◽  
Disease Control ◽  
Median Duration ◽  
Newly Diagnosed ◽  
Chronic Granulocytic Leukemia ◽  
Duration Of Disease ◽  
Granulocytic Leukemia ◽  
Disease Parameters

Thirty-three patients with newly diagnosed chronic granulocytic leukemia (CGL) were treated with melphalan between 1968 and 1976. Within 3 mo of beginning therapy subjective and objective disease parameters improved. Disease control was easily maintained with this agent until hematologic exacerbation occurred. The median duration of disease control was 25.3 mo, and the median duration of survival was 28.6 mo. Serious side effects were not produced. Thus melphalan appears to be another agent that may be used to control the manifestations of CGL prior to hematologic exacerbation.

Sign in / Sign up

Export Citation Format

Share Document